<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Abiraterone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Abiraterone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Abiraterone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="16459" href="/d/html/16459.html" rel="external">see "Abiraterone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12805570"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Yonsa;</li>
<li>Zytiga</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871214"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Abiraterone;</li>
<li>JAMP Abiraterone;</li>
<li>JAMP-Abiraterone;</li>
<li>MAR-Abiraterone;</li>
<li>NAT-Abiraterone;</li>
<li>PMS-Abiraterone;</li>
<li>REDDY-Abiraterone;</li>
<li>Sandoz Abiraterone;</li>
<li>Zytiga</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F10934413"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiandrogen;</li>
<li>
                        Antineoplastic Agent, Antiandrogen</li></ul></div>
<div class="block doa drugH1Div" id="F10934416"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients receiving abiraterone should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently (or have had a bilateral orchiectomy). Control BP and correct hypokalemia prior to and during treatment. Abiraterone acetate is available in different tablet formulations; use caution when selecting dosage form as dosing and food effects vary between products. The formulations are NOT interchangeable; do not substitute between formulations. Refer to "Administration" for information regarding an alternate abiraterone (Zytiga) administration method using a lower dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a0d01f-7598-4295-91fc-098cdd1ce6dd">Prostate cancer, metastatic, castration resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Zytiga:</i>
<b>Oral:</b> 1,000 mg once daily (in combination with prednisone 5 mg twice daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21612468','lexi-content-ref-25601341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21612468','lexi-content-ref-25601341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>or</b>
<i>(off-label combination; Zytiga</i>
<i>; BRCA-mutated disease): </i>
<b>Oral: </b>1,000 mg once daily (in combination with olaparib and prednisone or prednisolone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clarke.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clarke.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Yonsa (micronized formulation):</i>
<b>Oral: </b>500 mg once daily (in combination with methylprednisolone 4 mg twice daily).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad56ef6d-44af-4204-a290-a5a74a401b59">Prostate cancer, metastatic, high-risk, castration sensitive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, high-risk, castration sensitive:</b>
<i>Zytiga: </i>
<b>Oral: </b>1,000 mg once daily (in combination with prednisone 5 mg once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28578607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28578607'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>or</b>
<i>(off-label combination; Zytiga)</i>
<b>Oral: </b>1,000 mg once daily (in combination with prednisolone 5 mg once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28578639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28578639'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49131313-1b93-42b3-a036-395f4194beb8">Prostate cancer, synchronous metastatic, castration sensitive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, synchronous metastatic, castration sensitive (off-label combination):</b>
<i>Zytiga:</i>
<b>Oral:</b> 1,000 mg once daily (in combination with androgen deprivation, docetaxel [for 6 cycles], filgrastim, and prednisone 5 mg twice daily); continue abiraterone and prednisone until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35405085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35405085'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990929"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (&lt;5% excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25501058','lexi-content-ref-24374856','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25501058','lexi-content-ref-24374856','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31694496','lexi-content-ref-24374856','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31694496','lexi-content-ref-24374856','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31130566','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31130566','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988218"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment <b>
<i>prior to</i></b> treatment initiation:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (Child-Pugh class B): 250 mg once daily (Zytiga) or 125 mg once daily (Yonsa). Permanently discontinue if ALT and/or AST &gt;5 times the ULN or total bilirubin &gt;3 times ULN occur during treatment in patients with baseline moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe (Child-Pugh class C): Do not use.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity <b>
<i>during</i></b> treatment:</p>
<p style="text-indent:-2em;margin-left:4em;">ALT and/or AST &gt;5 times ULN <b>or</b> total bilirubin &gt;3 times ULN: Withhold treatment until liver function tests return to baseline or ALT and AST ≤2.5 times ULN and total bilirubin ≤1.5 times ULN, then reinitiate at 750 mg once daily (Zytiga) or 375 mg once daily (Yonsa).</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent hepatotoxicity on 750 mg/day (Zytiga) or 375 mg/day (Yonsa): Withhold treatment until liver function tests return to baseline or ALT and AST ≤2.5 times ULN and total bilirubin ≤1.5 times ULN, then reinitiate at 500 mg once daily (Zytiga) or 250 mg once daily (Yonsa).</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent hepatotoxicity on 500 mg once daily (Zytiga) or 250 mg once daily (Yonsa): Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT &gt;3 times ULN <b>and</b> total bilirubin &gt;2 times ULN (in the absence of biliary obstruction or other contributing cause responsible for concurrent elevation): Permanently discontinue treatment.</p></div>
<div class="block dot drugH1Div" id="F12805615"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Adrenocortical insufficiency: Increased corticosteroid doses may be required before, during, and after stress.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity: Refer to "Dosing: Hepatic Impairment".</p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia (in patients with diabetes): Antidiabetic medication dosage adjustments may be needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Mineralocorticoid excess (due to CYP17 inhibition): Concomitant administration with corticosteroids reduces the incidence and severity of these adverse events (eg, hypertension, hypokalemia, fluid retention). Control BP and correct hypokalemia prior to and during treatment.</p></div>
<div class="block doe drugH1Div" id="F10934417"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F12805580"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for use in combination with a corticosteroid.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (25% to 27%), hypertension (9% to 37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (15% to 22%), hyperglycemia (57%), hypernatremia (33%), hypertriglyceridemia (63%), hypokalemia (17% to 30%), hypophosphatemia (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (23%), diarrhea (18% to 22%), dyspepsia (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (7% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (13%), lymphocytopenia (20% to 38%; grades 3/4: 4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (11% to 46%), increased serum aspartate aminotransferase (15% to 37%), increased serum bilirubin (7% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (39%), insomnia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤30%), joint swelling (≤30%), myalgia (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (7% to 17%), dyspnea (12%), nasopharyngitis (11%), upper respiratory infection (5% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (7%), cardiac failure (2% to 3%), chest discomfort (≤4%), chest pain (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Groin pain (7%), hematuria (10%), nocturia (6%), urinary frequency (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Falling (6%), headache (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Endocrine &amp; metabolic: Adrenocortical insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure, fulminant hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p></div>
<div class="block coi drugH1Div" id="F12805577"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to abiraterone acetate or any component of the formulation or container; patients who are or could become pregnant.</p></div>
<div class="block war drugH1Div" id="F12805578"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Adrenocortical insufficiency has been reported rarely. Concurrent infection, stress, or interruption of daily corticosteroids are associated with reports of adrenocortical insufficiency. Signs and symptoms of adrenocorticoid insufficiency could be masked by adverse events associated with mineralocorticoid excess. Increased corticosteroid doses may be required before, during, and after stress.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Severe hepatotoxicity (eg, fulminant hepatitis, acute liver failure, and death) has been reported. Significant increases in liver enzymes (including grade 3 and 4 events) have also been observed (higher likelihood in patients with baseline elevations), generally occurring in the first 3 months of treatment. The safety of retreatment after significant elevations (ALT or AST ≥20 times the ULN and/or total bilirubin ≥10 times ULN) has not been evaluated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mineralocorticoid excess: Increased mineralocorticoids due to CYP17 inhibition may result in hypertension, hypokalemia, and fluid retention (including grade 3 and 4 events). Concomitant administration with corticosteroids reduces the incidence and severity of these adverse events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: May cause hypertension, hypokalemia, and fluid retention. QT prolongation and torsades de pointes have been observed rarely (postmarketing reports) in patients who developed hypokalemia during abiraterone administration. Monitor patients with cardiovascular disease closely, particularly those with heart failure, recent MI, or ventricular arrhythmia. Patients with left ventricular ejection fraction (LVEF) &lt;50% or NYHA class II, III, or IV heart failure were excluded from clinical trials. Monitor at least monthly for hypertension, hypokalemia, and fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes; severe hypoglycemia has been reported, particularly in patients receiving concomitant therapy with thiazolidinediones (eg, pioglitazone) or repaglinide. Antidiabetic medication dosage adjustments may be needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radium Ra 223 dichloride: Due to an increased risk of fractures and mortality, the use of abiraterone plus a corticosteroid in combination with radium Ra 223 dichloride is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Tablet formulations: Abiraterone acetate is available in different tablet formulations (the conventional formulation [Zytiga] and a micronized [fine particle] formulation [Yonsa]); use caution when selecting dosage form as dosing and food effects vary between products. The formulations are NOT interchangeable; do not substitute between formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Food: The manufacturer for abiraterone (Zytiga) recommends administering on an empty stomach (administer at least 1 hour before and 2 hours after any food); abiraterone AUC (exposure) may be increased up to 10-fold if administered with a meal. Abiraterone micronized (Yonsa) may be administered without regard to food.</p></div>
<div class="block dosfc drugH1Div" id="F50596744"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone acetate is available in different tablet formulations (the conventional formulation and a micronized [fine particle] formulation). The formulations are NOT interchangeable; do not substitute between formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">Zytiga 250 mg tablets are produced in film-coated and uncoated tablets; only the uncoated tablets are available in the United States. Zytiga 500 mg tablets are film-coated. Yonsa is a micronized formulation of abiraterone.</p></div>
<div class="block foc drugH1Div" id="F12805632"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yonsa: 125 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zytiga: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F12805571"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322870"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Abiraterone Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $1.60 - $97.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $195.51 - $206.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Yonsa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $100.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zytiga Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $108.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $217.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871215"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zytiga: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block adm drugH1Div" id="F10934418"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Abiraterone acetate is available in different tablet formulations; use caution when selecting dosage form as dosing and food effects vary between products. The formulations are NOT interchangeable; do not substitute between formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Swallow tablets whole with water. Do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Zytiga: Administer on an empty stomach, at least 1 hour before and 2 hours after food (per the manufacturer); no food should be consumed for at least 2 hours before or for at least 1 hour after the dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Data from a small, phase 2 study suggest that abiraterone (Zytiga) 250 mg once daily administered with or within 30 minutes of a low-fat breakfast is noninferior to the standard dose (1,000 mg) administered on an empty stomach; prostate-specific antigen and progression-free survival results were similar between the 2 arms, although higher troughs were reported with the standard dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29590007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29590007'])">Ref</a></span>). Low-dose abiraterone may decrease patient financial burden and improve adherence for those in resource-poor settings; further study is necessary to determine long-term efficacy of this dosing approach.</p>
<p style="text-indent:-2em;margin-left:6em;">Yonsa (micronized formulation): May be administered without regard to food.</p></div>
<div class="block hazard drugH1Div" id="F49104350"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F12805572"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of metastatic, castration-resistant prostate cancer (in combination with prednisone [Zytiga] or methylprednisolone [Yonsa])</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of metastatic, high-risk castration-sensitive prostate cancer (in combination with prednisone [Zytiga])</p></div>
<div class="block mst drugH1Div" id="F16141143"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Abiraterone may be confused with apalutamide</p>
<p style="text-indent:-2em;margin-left:4em;">Zytiga may be confused with Jevtana, Xgeva, Xofigo, Xtandi, Zometa, Zydelig</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage formulation issues: </b>Abiraterone acetate is available in different tablet formulations (the conventional formulation [Zytiga] and a micronized [fine particle] formulation [Yonsa]); use caution when selecting dosage form as dosing and food effects vary between products. The formulations are NOT interchangeable; do not substitute between formulations.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298629"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C8 (weak), CYP2D6 (moderate)</p></div>
<div class="block dri drugH1Div" id="F12817652"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Amitriptyline. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amoxapine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amoxapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Atomoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose when treating indications other than major depressive disorder.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ClomiPRAMINE. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Abiraterone Acetate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Abiraterone Acetate. Management: Avoid when possible. If the combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during combined use. Reduce abiraterone dose back to the prior dose and frequency once strong inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Daprodustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Dextromethorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Topical): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Antiandrogens may diminish the diagnostic effect of Flotufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Antiandrogens may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Abiraterone Acetate may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iboga. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Imipramine. Concentrations of desipramine may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Imipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofepramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lofepramine. The active metabolite of lofepramine is desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoclopramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nortriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nortriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perhexiline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perphenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Antiandrogens may diminish the diagnostic effect of Piflufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Protriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radium Ra 223 Dichloride: May enhance the adverse/toxic effect of Abiraterone Acetate. Specifically, the risk for fractures and death may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Abiraterone Acetate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Abiraterone Acetate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the therapeutic effect of Abiraterone Acetate. Management: Consider alternatives to the combined use of spironolactone and abiraterone. If combined, monitor the clinical response to abiraterone closely, looking specifically for signs of clinical failure and/or disease progression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Abiraterone Acetate may enhance the hypoglycemic effect of Thiazolidinediones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Trimipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F12805585"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Taking abiraterone with a high-fat meal may increase systemic exposure (up to 10-fold [Zytiga] or up to ~4-fold [Yonsa]). Management: Do not administer with food (Zytiga). According to the manufacturer, abiraterone (Zytiga) must be taken on an empty stomach, at least 1 hour before and 2 hours after food. Abiraterone micronized (Yonsa) may be administered with or without food.</p></div>
<div class="block rep_considerations drugH1Div" id="F49078254"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with partners who could become pregnant should use effective contraception during treatment and for 3 weeks after the last abiraterone dose.</p>
<p style="text-indent:0em;margin-top:2em;">Abiraterone is available in uncoated and film-coated tablets and in micronized tablets; the manufacturer recommends patients who could become pregnant wear gloves if handling uncoated tablets, micronized tablets, or tablets that are broken, crushed, or damaged.</p></div>
<div class="block pri drugH1Div" id="F12805574"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and adverse effects observed in animal reproduction studies, abiraterone may cause fetal harm or fetal loss if administered during pregnancy. Abiraterone is not indicated for use in females.</p>
<p style="text-indent:0em;margin-top:2em;">Abiraterone is available in uncoated and film-coated tablets and in micronized tablets; the manufacturer recommends patients who are pregnant wear gloves if handling uncoated tablets, micronized tablets, or tablets that are broken, crushed, or damaged.</p></div>
<div class="block brc drugH1Div" id="F12805576"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if abiraterone is present in breast milk. Abiraterone is not indicated for use in females.</p></div>
<div class="block mop drugH1Div" id="F12805623"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ALT, AST, and bilirubin prior to treatment, every 2 weeks for 3 months and monthly thereafter; if baseline moderate hepatic impairment (Child-Pugh class B), monitor ALT, AST, and bilirubin prior to treatment, weekly for the first month, every 2 weeks for 2 months then monthly thereafter. If hepatotoxicity develops during treatment (and only after therapy is interrupted and liver function tests have returned to safe levels), monitor ALT, AST, and bilirubin every 2 weeks for 3 months and monthly thereafter. Monitoring of testosterone levels is not necessary. Serum potassium (prior to treatment and at least monthly). Monitor blood glucose (in patients with diabetes) during and after discontinuation of abiraterone therapy. Monitor BP and monitor for fluid retention (prior to treatment and at least monthly).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor closely for signs/symptoms of adrenocorticoid insufficiency (if clinically indicated, consider appropriate diagnostics to confirm adrenal insufficiency) and signs/symptoms of hepatotoxicity (evaluate liver function promptly with signs or symptoms of hepatotoxicity). Monitor adherence.</p>
<p style="text-indent:0em;margin-top:2em;">Cardiovascular monitoring for patients with prostate cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; baseline and serial ECGs are recommended in patients at risk of QTc prolongation during androgen deprivation therapy (ADT); estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually during ADT (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F12805588"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Abiraterone selectively and irreversibly inhibits CYP17 (17 alpha-hydroxylase/C17,20-lyase), an enzyme required for androgen biosynthesis which is expressed in testicular, adrenal, and prostatic tumor tissues. Inhibits the formation of the testosterone precursors dehydroepiandrosterone (DHEA) and androstenedione.</p></div>
<div class="block phk drugH1Div" id="F12805591"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 19,669 ± 13,358 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%; to albumin and alpha<sub>1</sub>-acid glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Abiraterone acetate is hydrolyzed to the active metabolite abiraterone; further metabolized to inactive metabolites abiraterone sulphate and N-oxide abiraterone sulphate via CYP3A4 and SULT2A1</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Systemic exposure is increased by food</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 14.4 to 16.5 hours (Acharya 2012); prolonged in patients with mild and moderate hepatic impairment, ~18 and ~19 hours, respectively </p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 hours (Acharya 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~88%); urine (~5%)</p></div>
<div class="block phksp drugH1Div" id="F51219205"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: After a single oral 1,000 mg dose (Zytiga), systemic exposure increased ~1.1- and 3.6-fold in subjects with mild and moderate hepatic impairment, respectively. The mean half-life was prolonged to ~18 hours and ~19 hours in subjects with mild and moderate impairment, respectively. Systemic exposure of abiraterone increased by 7- fold and the fraction of free drug increased by 2-fold in subjects with severe baseline hepatic impairment. Mean protein binding was found to be lower in patients with severe hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13733202"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aberic | Abiranova | Abirateron a | Abiraterona Glenmark | Abiraterona lafedar | Adyard | Alvudin | Astrodil | Birat | Bitera | Dinogared | Flonax | Javulas | Kestava | Kigar | Kinned | Prosterona | Roterona | Tebiran | Tygarona | Zytiga | Zyvalix</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Abiral | Abirateron 1a pharma | Abirateron aristo | Abirateron G.L | Abirateron krka | Abirateron mylan | Abirateron sandoz | Abirateron stada | Abiraterone accord | Zytiga</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone | Zytiga</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Abiret | Zyterone | Zytiga | Zytix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone accord | Abiraterone krka | Abiraterone mylan | Bixodalan | Zytiga</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone krka | Abiraterone pharmascience | Abiraterone richter | Abiraterone sandoz | Abiraterone stada | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Abba | Acetato de abiraterona | Matiz | Rarija | Venomy | Zostide | Zytiga</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Abirateron accord | Abirateron Spirig HC | Abiraterone sandoz | Zytiga</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Abatero | Abirand | Abiravitae | Matiz | Zytiga | Zyvalix</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Abirand | Abirasun | Arabitro | Biranona | Nexterona | Teronred | Zytiga | Zyvalix</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Abirateron stada | Abirateron teva | Abiraterone accord | Abiraterone glenmark | Abiraterone mylan | Abiraterone richter | Abiraterone sandoz | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abibam | Abiranio | Abiratel | Abirateron accord | Abirateron al | Abirateron aristo | Abirateron biomo | Abirateron heumann | Abirateron hexal | Abirateron ratiopharm | Abirateron stada | Abirateron sun | Abirateron uropharm | Abirateron zentiva | Abiraterone glenmark | Abiraterone medac | Zytiga</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Abiratral | Zytiga</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Abiraterona acetato | Abiraterona lafedar | Abiratral | Abiravitae | Acetato de abiraterona | Zytiga | Zyvalix</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone accord | Abiraterone g.l. pharma | Abiraterone mylan | Abiraterone noramed | Abiraterone richter | Abiraterone sandoz | Abiraterone teva | Abiraterone viasana | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abiraterona accord | Abiraterona cipla | Abiraterona combix | Abiraterona dr reddys | Abiraterona Glenmark | Abiraterona kern | Abiraterona krka | Abiraterona mylan | Abiraterona normon | Abiraterona ohre pharma | Abiraterona sandoz | Abiraterona stada | Abiraterona teva | Zytiga</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abirateron avansor | Abirateron sandoz | Abiraterone accord | Abiraterone glenmark | Abiraterone krka | Abiraterone mylan | Abiraterone orion | Abiraterone ratiopharm | Abiraterone stada | Zytiga</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone accord | Abiraterone acetate zydus | Abiraterone arrow | Abiraterone biogaran | Abiraterone eg | Abiraterone evolugen | Abiraterone krka | Abiraterone mylan | Abiraterone sandoz | Abiraterone teva | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone | Abiraterone accord | Abiraterone sandoz | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone ariti | Abiraterone faran | Abiraterone sandoz | Jilidea | Zytiga</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Abaxan | Abirateron stada | Abirateron teva | Abirateron zentiva | Abiraterone accord | Abiraterone g.l. | Abiraterone krka | Abiraterone pharmascience | Abiraterone qilu | Abiraterone richter | Abiraterone sandoz | Abiraterone vipharm | Grumabix | Zytiga</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Abiranat | Birato | Zytiga</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone | Abiraterone accord | Abiraterone clonmel | Abiraterone krka | Abiraterone teva | Zytiga</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Abatitor | Abiracure | Abirapro | Abiratas | Abiron | Abisam | Abitate | Abretone | Abstet | Abura | Ahabir | Arbitus | Avirat | Bdron | Celbira | Mytera | Samtica | Xbira | Xostiv | Zabpro | Zecyte | Zybiraa | Zytiga | Zytiprost</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone ipi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone accord | Abiraterone eg | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Abiron | Arabitro | Zytiga</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone accord | Abiraterone g.l. pharma | Abiraterone krka | Abiraterone mylan | Abiraterone noramed | Abiraterone richter | Abiraterone sandoz | Abiraterone stada | Abiraterone teva | Abiraterone viasana | Abiraterone zentiva | Tatica | Zytiga</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Abirateron mylan | Abiraterone accord | Zytiga</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone accord | Abiraterone g.l. pharma | Abiraterone krka | Abiraterone mylan | Abiraterone noramed | Abiraterone richter | Abiraterone sandoz | Abiraterone stada | Abiraterone zentiva | Tatica | Zytiga</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone GT | Zytiga</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Abiratred | Artesto | Zytiga</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone | Abiraterone krka | Abiraterone sandoz | Abiraterone teva | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Abirateron sandoz | Abiraterone accord | Abiraterone glenmark | Abiraterone stada | Zytiga</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone | Zytiga</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Abipro | Abiraterona | Abiravitae | Baxomil | Birato | Zytiga</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone | Zytiga</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone g.l. pharma | Abiraterone orion | Abiraterone richter | Abiraterone vipharm | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Yonsa | Zytiga</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Abiraterona accord | Abiraterona bluepharma | Abiraterona mylan | Abiraterona sandoz | Abiraterona stada | Abiraterona teva | Abiraterona zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Abiraterona acetato khairi | Abiraterona varifarma | Abiratral | Bitera | Zytiga | Zyvalix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Birato | Zytiga</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Abiraterona stada | Abiraterona zentiva | Abiraterone accord | Bixodalan | Zytiga</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Abiraprost | Abirat | Abiraterone | Abiraterone AF | Abiraterone nv | Abiraterone sun | Abiraterone TL | Abitera | Amiranta | Teronred | Zytiga</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone SPC | Abremia | Zytiga</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abirateron avansor | Abirateron Medical Valley | Abirateron sandoz | Abiraterone accord | Abiraterone glenmark | Abiraterone krka | Abiraterone medac | Abiraterone mylan | Abiraterone orion | Abiraterone qilu | Abiraterone stada | Abiraterone zentiva | Zytiga</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Arabitro | Zytiga</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Abirateron accord | Abirateron krka | Abirateron mylan | Bixodalan | Zytiga</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Abirateron krka | Abirateron sandoz | Abirateron stada | Abiraterone | Abiraterone accord | Abiraterone g.l. pharma | Abiraterone glenmark | Abiraterone heaton | Abiraterone mylan | Abiraterone vipharm | Abiraterone zentiva | Tatica | Zytiga</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Abiratred | Zytiga</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Abetyl | Abiratex | Abitiga | Abyga | Arvila | Dipon | Zateron | Zytiga</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Abiratred | Zytiga</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abirateron vista | Teronred | Zytiga</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Abiratral | Adyard | Kestava | Zytiga | Zyvalix</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bdron</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Abiraterone Cipla | Teronred | Zybera | Zytiga</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Zytiga</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22526411">
<a name="22526411"></a>Acharya M, Bernard A, Gonzalez M, et al. Open-Label, Phase I, Pharmacokinetic Studies of Abiraterone Acetate in Healthy Men. <i>Cancer Chemother Pharmacol</i>. 2012;69(6):1583-1590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/22526411/pubmed" id="22526411" target="_blank">22526411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.<i> J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19470933">
<a name="19470933"></a>Attard G, Reid AH, A’Hern R, et al. Selective Inhibition of CYP17 With Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. <i>J Clin Oncol</i>. 2009;27(23):3742-3748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/19470933/pubmed" id="19470933" target="_blank">19470933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clarke.1">
<a name="Clarke.1"></a>Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. <i>NEJM Evidence</i>. doi:10.1056/EVIDoa2200043. Published online June 3, 2022. Accessed June 6 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159814">
<a name="20159814"></a>Danila DC, Morris MJ, de Bono JS, et al. Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer. <i>J Clin Oncol</i>. 2010;28(9):1496-1501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/20159814/pubmed" id="20159814" target="_blank">20159814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21612468">
<a name="21612468"></a>de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New Engl J Med\</i>. 2011;364(21):1995-2005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/21612468/pubmed" id="21612468" target="_blank">21612468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31694496">
<a name="31694496"></a>Eryılmaz MK, Karaağaç M. Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis. <i>J Oncol Pharm Pract.</i> 2019;25(8):2031-2034. doi:10.1177/1078155218818250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/31694496/pubmed" id="31694496" target="_blank">31694496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35405085">
<a name="35405085"></a>Fizazi K, Foulon S, Carles J, et al; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. <i>Lancet</i>. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/35405085/pubmed" id="35405085" target="_blank">35405085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22995653">
<a name="22995653"></a>Fizazi K, Scher HI, Molina A, et al. Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. <i>Lancet Oncol</i>. 2012;13(10):983-992.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/22995653/pubmed" id="22995653" target="_blank">22995653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28578607">
<a name="28578607"></a>Fizazi K, Tran N, Fein L,et al; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. <i>N Engl J Med</i>. 2017;377(4):352-360. doi: 10.1056/NEJMoa1704174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/28578607/pubmed" id="28578607" target="_blank">28578607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25501058">
<a name="25501058"></a>Francini E, Petrioli R, Fiaschi AI, Laera L, Roviello G. Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer. <i>Medicine (Baltimore)</i>. 2014;93(27):e163. doi:10.1097/MD.0000000000000163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/25501058/pubmed" id="25501058" target="_blank">25501058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28578639">
<a name="28578639"></a>James ND, de Bono JS, Spears MR, et al; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy.<i> N Engl J Med</i>. 2017;377(4):338-351. doi: 10.1056/NEJMoa1702900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/28578639/pubmed" id="28578639" target="_blank">28578639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31130566">
<a name="31130566"></a>Kimata R, Tomita Y, Kondo Y. Safety of abiraterone acetate administration in elderly patients receiving peritoneal dialysis with castration-resistant prostate cancer: two case reports. <i>J Nippon Med Sch.</i> 2019;86(2):135-138. doi:10.1272/jnms.JNMS.2019_86-211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/31130566/pubmed" id="31130566" target="_blank">31130566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24374856">
<a name="24374856"></a>Marbury T, Lawitz E, Stonerock R, et al. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. <i>J Clin Pharmacol</i>. 2014;54(7):732-41. doi:10.1002/jcph.253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/24374856/pubmed" id="24374856" target="_blank">24374856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159823">
<a name="20159823"></a>Reid AH, Attard G, Danila DC, et al. Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate. <i>J Clin Oncol</i>. 2010;28(9):1489-1495.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/20159823/pubmed" id="20159823" target="_blank">20159823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21632851">
<a name="21632851"></a>Ryan CJ, Shah S, Efstathiou E, et al. Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant With Serologic Response. <i>Clin Cancer Res</i>. 2011;17(14):4854-4861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/21632851/pubmed" id="21632851" target="_blank">21632851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23228172">
<a name="23228172"></a>Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. <i>N Engl J Med</i>. 2013;368(2):138-148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/23228172/pubmed" id="23228172" target="_blank">23228172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25601341">
<a name="25601341"></a>Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncol</i>. 2015;16(2):152-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/25601341/pubmed" id="25601341" target="_blank">25601341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159824">
<a name="20159824"></a>Ryan CJ, Smith MR, Fong L, et al. Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. <i>J Clin Oncol</i>. 2010;28(9):1481-1488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/20159824/pubmed" id="20159824" target="_blank">20159824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990618">
<a name="31990618"></a>Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. <i>J Clin Oncol</i>. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/31990618/pubmed" id="31990618" target="_blank">31990618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29150328">
<a name="29150328"></a>Stein CA, Levin R, Given R, et al. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. <i>Urol Oncol.</i> 2018;36(2):81.e9-81.e16. doi: 10.1016/j.urolonc.2017.10.018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/29150328/pubmed" id="29150328" target="_blank">29150328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29590007">
<a name="29590007"></a>Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer.<i> J Clin Oncol.</i> 2018;36(14):1389-1395. doi:10.1200/JCO.2017.76.4381<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/29590007/pubmed" id="29590007" target="_blank">29590007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22752297">
<a name="22752297"></a>Tolcher AW, Chi KN, Shore ND, et al. Effect of Abiraterone Acetate Plus Prednisone on the QT Interval In Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Chemother Pharmacol</i>. 2012;70(2):305-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abiraterone-drug-information/abstract-text/22752297/pubmed" id="22752297" target="_blank">22752297</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5November 17, 2016.</div>
</li>
<li>
<div class="reference">
                  Yonsa (abiraterone acetate) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; July 2022.</div>
</li>
<li>
<div class="reference">
                  Zytiga (abiraterone) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2021.</div>
</li>
<li>
<div class="reference">
                  Zytiga (abiraterone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 16083 Version 463.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
